Process intensification has become a hot topic in biopharma in recent years, with concepts like continuous manufacturing and “scaling-out” increasingly cited as investment drivers by drug firms and ...
As demand for biologics surges, the biopharmaceutical industry is under pressure to increase productivity and flexibility as well as shorten production timelines. At the same time, there is the need ...
Process intensification has reduced the cost of mAb manufacturing, but tweaks across bioproduction will be needed to reduce ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results